<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468168</url>
  </required_header>
  <id_info>
    <org_study_id>26-005</org_study_id>
    <nct_id>NCT01468168</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients</brief_title>
  <official_title>A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <brief_summary>
    <textblock>
      To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear volume increase from baseline</measure>
    <time_frame>baseline and 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>DE-101 Ophthalmic Suspension High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-101 Ophthalmic Suspension Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-101 Ophthalmic Suspension Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-101 Ophthalmic Suspension</intervention_name>
    <description>Ophthalmic suspension; QID</description>
    <arm_group_label>DE-101 Ophthalmic Suspension High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-101 Ophthalmic Suspension</intervention_name>
    <description>Ophthalmic suspension; QID</description>
    <arm_group_label>DE-101 Ophthalmic Suspension Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-101 Ophthalmic Suspension Vehicle</intervention_name>
    <description>Ophthalmic suspension vehicle; QID</description>
    <arm_group_label>DE-101 Ophthalmic Suspension Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals considered for entry into the study will be of either sex and any race who
             have:

          -  a confirmed diagnosis of dry eye,

          -  are willing to use no ocular treatments during the study other than study medication,

          -  have a corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity
             score of +0.7 logarithm of the minimum angle of resolution (logMAR) or better in each
             eye,

          -  will not use contact lenses during the study,

          -  Females of child-bearing potential must have a negative urine pregnancy test and be
             willing to use an acceptable method of contraception to be eligible for, and continue
             participation in, the study,

          -  18 years of age or older,

          -  able to understand and provide written informed consent

        Exclusion Criteria:

          -  Subjects with any of the following are not eligible to participate in the study:

          -  Fluorescein corneal staining or conjunctival staining that is too severe

          -  Conditions requiring the use of ophthalmic prescription or over the counter
             medications during the study (except for study medications)

          -  Any type of current punctal occlusion including punctal plugs, intracanalicular
             punctal plugs or cauterized puncta

          -  Any type of ocular surgery within 90 days prior to Visit 1 (Day 1)

          -  Known history of Steven-Johnson's syndrome, Riley-Day syndrome, and/or ocular
             pemphigoid

          -  Ocular(including lid)disease/abnormality that may interfere with the study

          -  Corneal transplant in either eye, at any time prior to enrollment in the study

          -  Laser refractive surgery less than one year prior to Visit 1 (Day 1)

          -  Conditions requiring the use of any systemic medication that is not ongoing at a
             stable dosage for at least 30 days prior to Visit 1 (Day 1)

          -  Application of isotretinoin within 30 days prior to Visit 1 (Day 1)

          -  Known allergy or sensitivity to any of the study medication components

          -  Uncontrolled systemic conditions or other conditions which would confound the study
             evaluations or endanger the safety of the subject

          -  A woman who is pregnant, nursing, or planning a pregnancy

          -  Participation in another investigational drug or vaccine trial, or participation in
             such a trial within 30 days prior to Visit 1 (Day 1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>New Port Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 14, 2017</submitted>
    <returned>May 19, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

